8 completed, 2 active not recruiting, 1 recruiting. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Danicopan - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 6 | 2025-08-11 | 2025-12-23 |
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH Danicopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 80 | 2022-10-28 | 2026-06-18 |
| A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets - Sickle Cell Disease | Phase 3 | Active not recruiting | Forma Therapeutics, Inc. | 450 | 2021-01-29 | 2026-04-06 |
| Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) Danicopan, Placebo, C5 Inhibitor - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 86 | 2020-12-16 | 2025-05-04 |
| Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH Elizaria®, Soliris® - Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome | Phase 3 | Completed | AO GENERIUM | 32 | 2017-11-29 | 2021-09-01 |
| Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria Paracetamol - Malaria | Phase 3 | Completed | Menzies School of Health Research | 360 | 2016-10-01 | 2019-12-19 |
| Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria Tafenoquine, Tafenoquine Placebo, Chloroquine - Malaria, Vivax | Phase 3 | Completed | GlaxoSmithKline | 251 | 2015-04-30 | 2018-05-16 |
| Rituximab in Auto-Immune Hemolytic Anemia rituximab (Mabthera®), Placebo - Warm Autoimmune Hemolytic Anemia | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 32 | 2011-03-03 | 2017-10-19 |
| Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Alemtuzumab, Rituximab - Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune | Phase 2 / Phase 3 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 19 | 2008-08-01 | 2010-08-30 |
| L-Arginine and Sickle Cell Disease L-arginine, Placebo - Sickle Cell Disease | Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 40 | 2006-09-01 | 2010-06-11 |
| Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) eculizumab - Paroxysmal Hemoglobinuria, Nocturnal | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 187 | 2005-05-01 | 2018-03-13 |
Hemoglobinuria, Paroxysmal (5) · Anemia (4) · Anemia, Hemolytic (2) · Anemia, Sickle Cell (2) · Hematologic Diseases (2) · Anemia, Hemolytic, Autoimmune (1) · Bone Marrow Diseases (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Hemoglobinuria (1) · Malaria (1) · Malaria, Vivax (1) · Proteinuria (1) · Pulmonary Arterial Hypertension (1)
Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Hemic and Lymphatic Diseases (9) · Hematologic Diseases (7) · Anemia, Hemolytic (6) · Anemia (5) · Myelodysplastic Syndromes (5) · Bone Marrow Diseases (4) · Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Infections (2) · Mosquito-Borne Diseases (2) · Parasitic Diseases (2) · Protozoan Infections (2) · Signs and Symptoms (2)
danicopan (3) · Rituximab (2) · eculizumab (2) · Acetaminophen (1) · Alemtuzumab (1) · Arginine (1) · Chloroquine (1) · Primaquine (1) · tafenoquine (1)
Alexion Pharmaceuticals, Inc. (4) · AO GENERIUM (1) · Assistance Publique - Hôpitaux de Paris (1) · Forma Therapeutics, Inc. (1) · GlaxoSmithKline (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Hospital de Clinicas de Porto Alegre (1) · Menzies School of Health Research (1)
France (6) · Canada (5) · United Kingdom (5) · Brazil (4) · Italy (4) · Spain (4) · United States (4) · Germany (3) · Greece (3) · Malaysia (3) · Thailand (3) · Czechia (2) · Israel (2) · Japan (2) · Netherlands (2)
Arjen Dondorp, MD (1) · Bridget Barber, MBBS (1) · Daniel Cooper, MBChB (1) · David Gomez-Almaguer, MD (1) · Giri M Rajahram, MD (1) · Jayaram Menon, MBBS (1) · Katherine Plewes, MD (1) · Matthew Grigg, MBBS (1) · Nicholas Anstey, PhD (1) · Oksana A. Markova, MD (1) · Timothy William, MBBS (1) · Tsin Yeo, MBBS (1)
PMID 17702897, PMID 20841509, PMID 29690924, PMID 30650326, PMID 34398258, PMID 35019238, PMID 35180298, PMID 35732155, PMID 37254256, PMID 38030318, PMID 39700502
2008 (1), 2019 (1)